Xtant Medical HoldingsNYSE American: XTNT

Xtant Medical Holdings, Inc. (NYSE:XTNT ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Brett Maas - IR Sean Browne - President and CEO Scott Neils - CFO Conference Call Participants Operator Welcome to the Xtant Medical Holdings, Inc. Third Quarter 2024 Conference Call. At this time all participants are in a listen only mode.

BELGRADE, MT / ACCESSWIRE / November 11, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced announced that Sean Browne, CEO and Scott Neils, CFO will be attending the following upcoming conference: Event: 15th Annual Craig-Hallum Alpha Select Conference Date: November 19, 2024Location: Sheraton NY Times Square Hotel, New York, NYFormat: 1x1 Meetings For more information, please visit: https://www.meetmax.com/sched/event_110237/conference_home.html?bank_access=0&event_id=110237 About Xtant Medical Holdings, Inc. Xtant Medical's mission of honoring the gift of donation so that our patients can live as full and complete a life as possible, is the driving force behind our company. Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures.

Xtant Medical Holdings, Inc. (NYSE:XTNT ) Q2 2024 Earnings Conference Call August 9, 2024 9:00 AM ET Company Participants Brett Maas - IR Sean Browne - President and CEO Scott Neils - CFO Conference Call Participants Ryan Zimmerman - BTIG Chase Knickerbocker - Craig-Hallum Capital Operator Welcome to the Xtant Medical Holdings, Inc. Second Quarter 2024 Conference Call. [Operator Instructions] I would now like to turn the call over to your host, Brett Maas, IR.

BELGRADE, MT / ACCESSWIRE / August 9, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the closing of its previously announced $5.0 million private placement with an existing institutional investor. The Company sold 7,812,500 shares of common stock at a purchase price of $0.64 per share.

BELGRADE, MT / ACCESSWIRE / August 8, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced it has entered into a securities purchase agreement with an existing institutional investor to sell shares of its common stock in a private placement. The Company agreed to issue an aggregate of 7,812,500 shares of common stock at a purchase price of $0.64 per share, resulting in gross proceeds of $5.0 million.

BELGRADE, MT / ACCESSWIRE / August 8, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the second quarter ended June 30, 2024, after the close of the financial markets on Thursday, August 8, 2024. Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call on Friday, August 9, 2024, at 9:00 AM ET to review results.

BELGRADE, MT / ACCESSWIRE / August 8, 2024 / Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the second quarter ended June 30, 2024. Second Quarter 2024 Financial Highlights Revenue of $29.9 million, up 48%, compared to the prior year quarter Gross margin of 62.1%, up 50 basis points, compared to the prior year quarter Net loss of $3.9 million compared to $2.2 million in the year ago quarter Positive Adjusted EBITDA; Adjusted EBITDA of $0.5 million compared to $0.1 million in the prior year quarter Recent Business Highlights Recently launched two new amniotic membrane allografts products, SimpliGraft™ and SimpliMax™; while Cortera™ reached record sales and users for the second quarter Signed 15 new distributors in the second quarter Awarded 20 IDN contracts in the second quarter Entered into a $5.0 million private placement on August 7, 2024 Sean Browne, President and CEO of Xtant Medical, stated, "Our second quarter financial results illustrate the positive momentum that is building as we head into the second half of 2024.

BELGRADE, Mont., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that management will participate in two upcoming investor conferences: